Methods for treating metastatic stage prostate cancer
AssigneeFerring International SA
InventorBo-Eric PERSSON
Life of this patent
Estimating the term…
Abstract
The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced prostate cancer.
Claims10
1-35. (canceled)
A method of treating prostate cancer in a subject in need thereof, the method comprising:
- testing the prostate specific antigen (PSA) of a potential subject;
- selecting the potential subject for treatment if the subject's PSA level is greater than or equal to 50 ng/mL;
- administering an initial dose of degarelix ranging from about 160 mg to about 320 mg to the subject;
- and administering at least one maintenance dose of degarelix ranging from about 60 mg to 160 mg to the subject,
- wherein the at least one maintenance dose is administered approximately 20 to 36 days after the previous dose of degarelix.
The method of 36, wherein the treated subject has at least a 95% likelihood of having a therapeutically low serum testosterone level of less than or equal to 0.5 ng/mL by day 28 of treatment.
Dependencies are inferred from the claim text.